Renascience

Renascience EBIT per Share

The EBIT per Share of Renascience (4889.T) as of Nov 19, 2026 is -25.90 JPY. In the previous year, EBIT per Share was -14.01 JPY — a change of 84.95% (lower).

EBIT per Share

-25.90JPY

YoY

84.95%

Last updated:

EBIT per Share of Renascience is 2026 -25.90 JPY. EBIT per Share of Renascience was 2025 -14.01 JPY. It decreases by 84.95% lower compared to the previous year.

The Renascience EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2020
-13.28 JPY
Jan 1, 2021
-6.25 JPY
Jan 1, 2022
-16.59 JPY
Jan 1, 2023
-26.26 JPY
Jan 1, 2024
-19.85 JPY
Jan 1, 2025
-14.01 JPY
Jan 1, 2026
-25.90 JPY
Jan 1, 2027 (e)
0.00 JPY
The Renascience EBIT per Share history
YEAREBIT per ShareYoY
est0.00JPY-100.00%
-25.90JPY+84.95%
-14.01JPY-29.44%
-19.85JPY-24.42%
-26.26JPY+58.35%
-16.59JPY+165.32%
-6.25JPY-52.94%
-13.28JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

EBIT per Share of Renascience is -25.90 JPY in 2026.

EBIT per Share of Renascience changed from -14.01 JPY to -25.90 JPY, representing a 84.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Renascience since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Renascience

All Key Metrics — Renascience